NCT07256405

Brief Summary

The value of next-generation sequencing (NGS) using Nanopore technology has been demonstrated in the case of diabetic patients' wounds or in prosthetic joint infections. The aim of this study is to demonstrate its relevance as a new diagnostic approach for fracture-related infections (FRI). Bone samples from patient with FRI will be submitted to shotgun metagenomic Next-generation sequencing using Oxford Nanopore Technology (ONT) in order to establish its diagnostic value in this context in comparison with the reference method.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

2 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 11, 2024

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

November 20, 2025

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 1, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

December 5, 2025

Status Verified

November 1, 2025

Enrollment Period

1.8 years

First QC Date

November 20, 2025

Last Update Submit

December 1, 2025

Conditions

Keywords

NanoporeFractureMetagenomicTraumaInfectionHigh throughput sequencing

Outcome Measures

Primary Outcomes (1)

  • Concordance between the microbiological documentation obtained by sequencing and that of the reference technique (culture)

    Metagenomic sequencing will be used to determine the microbiome of fracture-related infections. Data will be compared with those of reference microbiological identification techniques (culture).

    1 month

Secondary Outcomes (3)

  • Time to obtain final microbiological results by sequencing compared with the reference technique (culture)

    1 month

  • Number of cases in which an adjustment of targeted antibiotic therapy would be made based on NGS results.

    1 month

  • Microbial abundance defined by the number of reads (sequence reads) obtained per phylotype

    1 month

Study Arms (1)

Fracture-related infection

Patients suspected of having acute or chronic post-traumatic osteoarticular infection according to the criteria of the FRI (Fracture-Related Infection) consensus group and scheduled to undergo a bone and/or soft tissue biopsy as part of routine care

Diagnostic Test: Metagenomic sequencing

Interventions

Metagenomic sequencingDIAGNOSTIC_TEST

Samples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.

Fracture-related infection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients admitted to hospital following trauma for whom a fracture-related infection was diagnosed.

You may qualify if:

  • Age ≥ 18 years
  • Diagnosis of fracture-related infection (FRI consensus group)
  • Patient scheduled to undergo a bone and/or soft-tissue biopsy as part of routine care

You may not qualify if:

  • Patient opposition
  • Patient under a legal protection measure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

IHU, service des maladies infectieuses chroniques

Marseille, Bouches-du-Rhône, 13005, France

Location

Military Teaching Hospital Sainte Anne

Toulon, VAR, 83000, France

Location

Related Publications (5)

  • Tarabichi M, Shohat N, Goswami K, Alvand A, Silibovsky R, Belden K, Parvizi J. Diagnosis of Periprosthetic Joint Infection: The Potential of Next-Generation Sequencing. J Bone Joint Surg Am. 2018 Jan 17;100(2):147-154. doi: 10.2106/JBJS.17.00434.

  • Goswami K, Shope AJ, Tokarev V, Wright JR, Unverdorben LV, Ly T, Chen See J, McLimans CJ, Wong HT, Lock L, Clarkson S, Parvizi J, Lamendella R. Comparative meta-omics for identifying pathogens associated with prosthetic joint infection. Sci Rep. 2021 Dec 9;11(1):23749. doi: 10.1038/s41598-021-02505-7.

  • Sanderson ND, Street TL, Foster D, Swann J, Atkins BL, Brent AJ, McNally MA, Oakley S, Taylor A, Peto TEA, Crook DW, Eyre DW. Real-time analysis of nanopore-based metagenomic sequencing from infected orthopaedic devices. BMC Genomics. 2018 Sep 27;19(1):714. doi: 10.1186/s12864-018-5094-y.

  • Ivy MI, Thoendel MJ, Jeraldo PR, Greenwood-Quaintance KE, Hanssen AD, Abdel MP, Chia N, Yao JZ, Tande AJ, Mandrekar JN, Patel R. Direct Detection and Identification of Prosthetic Joint Infection Pathogens in Synovial Fluid by Metagenomic Shotgun Sequencing. J Clin Microbiol. 2018 Aug 27;56(9):e00402-18. doi: 10.1128/JCM.00402-18. Print 2018 Sep.

  • Walter N, Orbenes N, Rupp M, Alt V. The State of Research in Fracture-Related Infection-A Bibliometric Analysis. Medicina (Kaunas). 2022 Aug 29;58(9):1170. doi: 10.3390/medicina58091170.

Biospecimen

Retention: SAMPLES WITH DNA

tissue samples

MeSH Terms

Conditions

InfectionsFractures, BoneWounds and Injuries

Study Officials

  • LACÔTE-DELARBRE David, MD

    Military Teaching Hospital Sainte Anne

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2025

First Posted

December 1, 2025

Study Start

March 11, 2024

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

December 5, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Locations